Quantcast

Latest Astellas Pharma Inc. Stories

2011-06-09 07:16:00

SAN DIEGO and TOKYO, June 9, 2011 /PRNewswire-FirstCall/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study evaluating the investigational drug AC220, a potent and selective FLT3 inhibitor. The data will be presented in an oral session at the upcoming European Hematology Association (EHA) meeting in London. The abstract (#1019) can be accessed at the EHA Congress website at...

2011-06-06 08:13:00

DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago. The study was conducted at Agensys, Inc., a member of the Astellas global group of companies, which is developing a...

2011-05-19 12:00:00

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds. "Astellas has made...

2011-05-17 14:31:00

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

2011-05-03 08:30:00

DEERFIELD, Ill., May 3, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc. ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, welcomes four seasoned industry leaders to its team. New additions include Stephen Eck, M.D., Ph.D. as vice president, head of medical oncology, Karen Reeves, M.D. as vice president, global head of medical science, Mark Weinberg, M.D., MBA as therapeutic area head for central nervous system (CNS) and pain and Bernhardt Zeiher, M.D. as...

2011-04-29 06:05:00

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- First Quarter 2011 Highlights: Qutenza® (capsaicin) 8% patch purchased by 321 institutions, up from 239 in Q4 2010 Revenue of $3.2 million including $0.6 million U.S. Qutenza product revenue Operational focus enables lower planned expense growth in 2011 Qutenza sales initiated in Poland and Czech Republic by Astellas NGX-1998 Phase 2 clinical trial continues in postherpetic neuralgia (PHN) patients surpassing 65%...

2011-04-29 06:00:00

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief Executive Officer. Anthony DiTonno commented, "I have been CEO of NeurogesX for more than eight years and we have accomplished the objectives I...

2011-04-11 08:09:00

STAINES, England, April 11, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today announced the appointment of Ken Jones as its President and CEO. Mr Jones, who since July 2007 has held the position of COO at Astellas Pharma Europe Ltd., succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc., the U.S. subsidiary of...

2011-03-30 15:05:00

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Recent Highlights: Qutenza(®) (capsaicin) 8% patch launch in US by NeurogesX sales force drives early adoption by large US institutions; 238 hospitals purchased as of 4Q10, up 54% from 3Q10 Medicare Part B coverage confirmed Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza product revenue EU launch by Astellas advancing, with Qutenza available in 17 countries at December 31, 2010 NGX-1998 Phase 2...

2011-03-24 03:59:00

STAINES, England, March 24, 2011 /PRNewswire/ -- The Astellas European Foundation has today announced financial support to the Japanese Red Cross Society for their work to assist those impacted by the earthquake and tsunami on Friday, 11th March. The Japanese Red Cross Society is working with the local government of the affected region and the support will help provide aid to the local population. Mr. Ken Jones, Chief Operating Officer of Astellas Pharma Europe Ltd. and a Trustee of...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related